Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00867308 · ClinicalTrials.gov registry record · Phase 2
Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage Dysplasia
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Terminated
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT00867308 is a Phase 2 study that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 32 participants.
The verdict
NCT00867308, a Phase 2 study, was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is a phase II study of lenalidomide in patients with myelodysplastic syndrome (MDS) and with acute myeloid leukemia (AML) with trilineage dysplasia. Patients will receive two cycles of lenalidomide. Patients who respond may given additional cycles of lenalidomide until disease progression.
Interventions
- DRUG Lenalidomide 50 mg
- DRUG Lenalidomide 15 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2009-07 |
| Est. Completion | 2014-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00867308
The ClinicalTrials.gov registry entry for NCT00867308 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lenalidomide 50 mg is the first listed.
NCT00867308 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00867308 about?
NCT00867308 is a clinical study titled "Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage Dysplasia". This is a phase II study of lenalidomide in patients with myelodysplastic syndrome (MDS) and with acute myeloid leukemia (AML) with trilineage dysplasia. Patients will receive two cycles of lenalidomide. Patients who respond may given additional cycles of lenalidomide until disease progression.
What is the current status of trial NCT00867308?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2009-07. Estimated completion is 2014-05.
What interventions are being tested in trial NCT00867308?
The interventions under investigation include: Lenalidomide 50 mg (DRUG), Lenalidomide 15 mg (DRUG).
Who is sponsoring clinical trial NCT00867308?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.